SymBio Pharmaceuticals
Toranomon 30 Mori Building
3-2-2 Toranomon Minato-ku
Tokyo
105-0001
Tel: 03-5472-1125
Fax: 03-5472-3054
Website: http://www.symbiosis.co.jp/
Email: info@symbiosis.co.jp
13 articles about SymBio Pharmaceuticals
-
Eagle Pharmaceuticals’ Japanese Licensing Partner, SymBio, Receives Approval of TREAKISYM Ready-To-Dilute (“RTD”) Formulation, with Launch Expected in January 2021
9/23/2020
Eagle Pharmaceuticals, Inc. announced that its marketing partner, SymBio Pharmaceuticals Limited, has received regulatory approval for TREAKISYM ready-to-dilute liquid formulation from the Pharmaceuticals and Medical Devices Agency in Japan.
-
Eagle Pharmaceuticals’ Japanese Licensing Partner SymBio Announces Completion of Clinical Trial Enrollment for TREAKISYM® Rapid Infusion Liquid Bendamustine Formulation
3/30/2020
Eagle Pharmaceuticals, Inc. announced that its marketing partner SymBio Pharmaceuticals Limited has completed patient enrollment in a clinical trial for TREAKISYM rapid infusion, a liquid bendamustine injection with a 10-minute administration time, in Japan.
-
Eagle Pharmaceuticals’ Japanese Licensing Partner SymBio Announces its Submission of a New Drug Application for TREAKISYM® Ready-To-Dilute Formulation
10/7/2019
Eagle Pharmaceuticals, Inc. announced that its marketing partner SymBio Pharmaceuticals Limited has submitted a New Drug Application for TREAKISYM ready-to-dilute liquid formulation in Japan.
-
SymBio Pharmaceuticals: Initiation of Phase I Clinical Trial for Oral TREAKISYM in Progressive Solid Tumors
1/22/2018
SymBio Pharmaceuticals announced today that it has initiated a Phase 1 study in Japan for oral TREAKISYM in patients with progressive solid tumors.
-
Eagle Pharma Licenses Japanese Rights For Bendamustine Hydrochloride Ready-To-Dilute And Rapid Infusion Injection Products To SymBio Pharma
9/20/2017
-
SymBio Pharma Release: Initiation Of Phase III Clinical Trial On The Patient-Controlled Pain Management Drug "SyB P-1501"
6/13/2016
-
The Medicines Company And SymBio Pharmaceuticals Establish Strategic Partnership For IONSYS (Fentanyl Iontophoretic Transdermal System) In Japan
10/7/2015
-
SymBio Pharmaceuticals Announces Completion of Patient Enrollment of TREAKISYM(R) (SyB L-0501) Phase II Trial in Frontline Low-Grade Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
3/6/2013
-
SymBio Pharmaceuticals Announces Results Presented at American Society of Clinical Oncology 2012 Evaluating Clinical Benefits of TREAKISYM(R) (Bendamustine) in Combination With Rituximab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (
6/5/2012
-
Onconova Therapeutics Inc. and SymBio Pharmaceuticals Complete License Agreement for Rigosertib, a Phase III Stage Multi-Kinase Inhibitor for Cancer
7/8/2011
-
SymBio Pharmaceuticals Raises $24M in Series E
2/28/2011
-
SymBio Pharmaceuticals and Eisai Company, Ltd. to Launch Symbenda(R) in Singapore for the Treatment of Low-grade Non-Hodgkin's Lymphoma and Chronic Lymphatic Leukemia
9/7/2010
-
Abeille Pharmaceuticals, Inc. Licenses AB-1001 to SymBio Pharmaceuticals for Commercialization in Japan and Pacific Rim Countries
3/15/2007